Voya Investment Management LLC Buys 18,812 Shares of Harmony Biosciences Holdings, Inc. $HRMY

Voya Investment Management LLC raised its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 56.3% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 52,213 shares of the company’s stock after acquiring an additional 18,812 shares during the period. Voya Investment Management LLC owned approximately 0.09% of Harmony Biosciences worth $1,439,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in HRMY. Raymond James Financial Inc. boosted its stake in Harmony Biosciences by 288.2% in the 1st quarter. Raymond James Financial Inc. now owns 147,164 shares of the company’s stock valued at $4,884,000 after purchasing an additional 109,257 shares during the period. Wellington Management Group LLP acquired a new stake in shares of Harmony Biosciences during the first quarter worth $543,000. Hsbc Holdings PLC boosted its position in shares of Harmony Biosciences by 6.9% in the first quarter. Hsbc Holdings PLC now owns 21,803 shares of the company’s stock valued at $714,000 after acquiring an additional 1,402 shares during the period. Comerica Bank grew its stake in shares of Harmony Biosciences by 6.3% in the first quarter. Comerica Bank now owns 14,342 shares of the company’s stock valued at $476,000 after acquiring an additional 847 shares in the last quarter. Finally, Ieq Capital LLC bought a new position in Harmony Biosciences during the first quarter worth about $202,000. Institutional investors and hedge funds own 86.23% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on HRMY. Deutsche Bank Aktiengesellschaft decreased their target price on shares of Harmony Biosciences from $54.00 to $36.00 and set a “buy” rating on the stock in a research report on Thursday, September 25th. Mizuho increased their price target on Harmony Biosciences from $39.00 to $46.00 and gave the stock an “outperform” rating in a research report on Monday, December 1st. Wall Street Zen raised Harmony Biosciences from a “hold” rating to a “buy” rating in a report on Saturday, December 13th. Weiss Ratings reiterated a “hold (c)” rating on shares of Harmony Biosciences in a research report on Monday, December 22nd. Finally, HC Wainwright restated a “buy” rating on shares of Harmony Biosciences in a research report on Wednesday, December 3rd. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $45.63.

Harmony Biosciences Trading Down 0.6%

Shares of HRMY stock opened at $37.91 on Tuesday. Harmony Biosciences Holdings, Inc. has a fifty-two week low of $25.52 and a fifty-two week high of $40.93. The stock’s fifty day moving average price is $34.62 and its two-hundred day moving average price is $33.54. The company has a debt-to-equity ratio of 0.18, a quick ratio of 3.72 and a current ratio of 3.75. The company has a market cap of $2.18 billion, a PE ratio of 11.92, a P/E/G ratio of 0.48 and a beta of 0.80.

Harmony Biosciences (NASDAQ:HRMY) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $0.87 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.05). The business had revenue of $239.46 million for the quarter, compared to the consensus estimate of $222.68 million. Harmony Biosciences had a return on equity of 24.88% and a net margin of 22.50%. Equities analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current fiscal year.

Insider Activity at Harmony Biosciences

In other news, CEO Jeffrey M. Dayno sold 25,933 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $40.11, for a total value of $1,040,172.63. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 23.60% of the company’s stock.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.